Molecular Templates, Inc. (MTEM)
For informational purposes only. Not financial advice.
Molecular Templates, Inc. (MTEM) is a publicly traded company trading at $0.00 with a market cap of $658. It holds a moderate AI score of 68/100 based on fundamental, technical, and sentiment analysis.
Molecular Templates, Inc. is a clinical-stage biopharmaceutical company focused on developing biologic therapeutics for cancer and other serious diseases. Their proprietary biologic engineered toxin body (ETB) drug platform drives their pipeline of therapies.
Company Overview
Molecular Templates pioneers biologic engineered toxin body (ETB) therapeutics, offering a novel approach to cancer treatment with a pipeline of Phase I clinical trials and a strategic collaboration with Bristol Myers Squibb, positioning them for significant growth in the biotechnology sector.
Investment Thesis
Investing in Molecular Templates presents a compelling opportunity due to its innovative ETB platform and promising clinical pipeline. The company's focus on developing targeted therapies for cancer and other serious diseases addresses a significant market need. With multiple ETB candidates in Phase I clinical trials, including MT-5111, MT-0169, and MT-6402, Molecular Templates has the potential to generate significant value through successful clinical development and commercialization. The collaboration with Bristol Myers Squibb further validates the ETB platform and provides financial and strategic support. While the company's negative profit margin of -14.2% reflects its clinical-stage status, the high gross margin of 87.9% indicates the potential for strong profitability upon commercialization. Key value drivers include positive clinical trial results, expansion of the ETB pipeline, and further strategic partnerships.
Key Highlights
- Developing a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform.
- MT-5111 is in Phase I clinical trial for the treatment of HER2-positive cancers.
- MT-0169 is in Phase I clinical trial to treat relapsed/refractory myeloma patients.
- MT-6402 is in Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients.
- Collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets.
Competitors
Strengths
- Proprietary ETB platform technology.
- Pipeline of ETB candidates in clinical development.
- Collaboration agreement with Bristol Myers Squibb.
- High gross margin potential (87.9%).
Weaknesses
- Clinical-stage company with no currently approved products.
- Negative profit margin (-14.2%).
- Reliance on clinical trial success.
- Limited financial resources.
Catalysts
- Upcoming: Clinical trial readouts for MT-5111 in HER2-positive cancers.
- Upcoming: Clinical trial readouts for MT-0169 in relapsed/refractory myeloma.
- Upcoming: Clinical trial readouts for MT-6402 in PD-1/PD-L1 antibody relapsed/refractory patients.
- Ongoing: Expansion of the ETB pipeline to new targets.
- Ongoing: Potential for new strategic partnerships and collaborations.
Risks
- Potential: Clinical trial failures could delay or halt the development of ETB candidates.
- Potential: Regulatory hurdles could delay or prevent the approval of ETB candidates.
- Ongoing: Competition from other biotechnology companies could limit market share.
- Potential: Patent challenges could undermine the company's intellectual property.
- Ongoing: The company's limited financial resources could constrain its ability to fund research and development.
Growth Opportunities
- Expansion of ETB Pipeline: Molecular Templates has the opportunity to expand its pipeline of ETB-based therapies by targeting additional cancer-related targets. The market for targeted cancer therapies is estimated to reach $150 billion by 2028. By developing ETBs for targets such as CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45, the company can diversify its portfolio and increase its potential for commercial success. Timeline: Ongoing, with new targets identified and ETBs developed on a continuous basis.
- Advancement of Clinical Programs: The successful advancement of MT-5111, MT-0169, and MT-6402 through clinical trials represents a significant growth opportunity. Positive clinical trial results could lead to regulatory approval and commercialization, generating substantial revenue. The market for HER2-positive cancer therapies is estimated at $10 billion, while the market for myeloma therapies is estimated at $20 billion. Timeline: Ongoing, with clinical trial readouts expected over the next 2-3 years.
- Strategic Partnerships and Collaborations: Molecular Templates can leverage its ETB platform to establish additional strategic partnerships and collaborations with pharmaceutical companies. These partnerships can provide financial resources, expertise, and access to new markets. The collaboration with Bristol Myers Squibb demonstrates the potential for such partnerships. Timeline: Ongoing, with potential for new partnerships to be established in the near future.
- Expansion into New Therapeutic Areas: While currently focused on cancer, Molecular Templates could potentially expand its ETB platform into other therapeutic areas, such as autoimmune diseases or infectious diseases. The ETB platform's ability to target specific cells and deliver therapeutic payloads could be applicable to a wide range of diseases. Timeline: Long-term, with potential for expansion into new therapeutic areas in 5+ years.
- Out-Licensing and Commercialization: Upon successful completion of clinical trials and regulatory approval, Molecular Templates has the opportunity to out-license or commercialize its ETB-based therapies. Out-licensing agreements can generate upfront payments, milestone payments, and royalties. Commercialization can generate direct revenue from product sales. Timeline: Dependent on clinical trial outcomes and regulatory approvals, with potential for commercialization in 3-5 years.
Opportunities
- Expansion of ETB pipeline to new targets.
- Advancement of clinical programs to regulatory approval.
- Establishment of additional strategic partnerships.
- Expansion into new therapeutic areas.
Threats
- Clinical trial failures.
- Regulatory hurdles.
- Competition from other biotechnology companies.
- Patent challenges.
Competitive Advantages
- Proprietary ETB platform: The company's ETB platform is protected by patents and trade secrets, providing a competitive advantage.
- Clinical-stage pipeline: The company has a pipeline of ETB candidates in various stages of clinical development, creating a barrier to entry for competitors.
- Strategic partnerships: The company's collaboration with Bristol Myers Squibb provides access to resources and expertise, strengthening its competitive position.
About
Founded in 2001 and headquartered in Austin, Texas, Molecular Templates, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative biologic therapeutics. The company's core technology revolves around its proprietary biologic engineered toxin body (ETB) drug platform, which is designed to address unmet needs in cancer treatment and other serious diseases. Molecular Templates is focused on advancing a pipeline of ETB-based therapies, with several candidates currently in Phase I clinical trials. These include MT-5111 for HER2-positive cancers, MT-0169 for relapsed/refractory myeloma, and MT-6402 for PD-1/PD-L1 antibody relapsed/refractory patients. The company's research and development efforts extend beyond these clinical-stage assets, with a pipeline of ETBs in development targeting CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45. A key element of Molecular Templates' strategy is collaboration, exemplified by its agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. This partnership underscores the potential of the ETB platform and provides valuable resources for advancing the company's pipeline.
What They Do
- Discovers and develops biologic therapeutics.
- Focuses on treatments for cancer and other serious diseases.
- Utilizes its proprietary biologic engineered toxin body (ETB) drug platform.
- Develops ETB candidates for various cancer targets.
- Conducts Phase I clinical trials for its lead ETB candidates.
- Collaborates with pharmaceutical companies to develop novel products.
Business Model
- Develops and patents novel ETB-based therapeutics.
- Conducts preclinical and clinical trials to evaluate the safety and efficacy of its therapies.
- Seeks regulatory approval for its therapies from agencies such as the FDA.
- Commercializes its therapies through direct sales or partnerships.
Industry Context
Molecular Templates operates within the biotechnology industry, which is characterized by rapid innovation and intense competition. The company's focus on developing targeted therapies for cancer aligns with the broader industry trend towards personalized medicine. The market for cancer therapeutics is substantial and growing, driven by an aging population and increasing incidence of cancer. Molecular Templates competes with other biotechnology companies developing novel cancer therapies, including ACGJ (Accelerate Acquisition Corp), ALNAQ (Alnasca Technologies Inc), ARTH (ArTara Therapeutics Inc), BLEVF (BioLexis Therapeutics Inc), and EPRSQ (Eprogen Biosciences Inc). Success in this industry requires strong scientific expertise, robust clinical trial execution, and effective commercialization strategies.
Key Customers
- Patients suffering from cancer and other serious diseases.
- Healthcare providers who prescribe and administer the company's therapies.
- Pharmaceutical companies that partner with Molecular Templates to develop and commercialize its products.
Financials
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2024 | $572,000 | -$8M | $-1.23 |
| Q1 2024 | $11M | $572,000 | $0.08 |
| Q4 2023 | $7M | -$4M | $-0.73 |
| Q3 2023 | $7M | -$4M | $-0.82 |
Source: Company filings
Chart & Info
Price Chart
Molecular Templates, Inc. (MTEM) stock price: $0.00 (+0.00, +0.00%)
Why Bull
- •Recent insider buying suggests confidence in MTEM's future prospects, indicating that leadership believes in the company's direction.
- •Community sentiment has shifted positively, with discussions highlighting recent advancements in their drug pipeline and potential market impact.
- •The company has received favorable attention in biotech circles, with analysts noting its innovative approach to treatment solutions.
- •Positive news coverage has increased visibility, attracting interest from retail investors who are optimistic about the company's growth potential.
Why Bear
- •Concerns remain about the competitive landscape in the biotech sector, with several rivals advancing similar therapies that could dilute MTEM's market share.
- •Recent earnings reports have not met market expectations, leading to skepticism among investors regarding the company's short-term performance.
- •Social sentiment has also seen a rise in caution, with some investors expressing doubts about the sustainability of recent gains and overall market conditions.
- •Insider selling activity has raised red flags for some, suggesting that not all leadership is aligned with the company's long-term vision.
Latest News
No recent news available for MTEM.
Technical Analysis
Rationale
AI-generated technical analysis for MTEM including trend direction, momentum, and pattern recognition.
What to Watch
Key support and resistance levels, volume signals, and upcoming events.
Risk Management
Position sizing, stop-loss levels, and risk-reward assessment.
Community
Discussion
Share your analysis and discuss Molecular Templates, Inc. (MTEM) with other investors. Log in to post.
Sentiment
Community sentiment and discussion activity for MTEM.
Make a Prediction
Set your price target for Molecular Templates, Inc. (MTEM), choose a timeframe, and track your prediction accuracy.
Current price: $0.00
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MTEM.
Price Targets
Wall Street price target analysis for MTEM.
Insider Flow (30d)
No insider trades in the last 30 days.
MoonshotScore
Score Factors
-
Revenue Growth 10/100
Revenue surged 190.1% year-over-year, indicating explosive demand and rapid market share expansion.
-
Gross Margin 10/100
Gross margin of 87.9% shows excellent pricing power and a strong competitive moat.
-
Operating Leverage 6/100
Revenue growth is driving operating leverage, meaning profits can grow faster than costs.
-
Cash Runway 5/100
Limited cash of $12M could constrain flexibility; watch for dilution risk or debt issuance.
-
R&D Intensity 10/100
Investing 85.3% of revenue in R&D signals heavy commitment to innovation and future product pipeline.
-
Insider Activity 6/100
No significant insider buying or selling recently, which is neutral for the stock outlook.
-
Short Interest 5/100
Float and volume data unavailable for liquidity analysis.
-
Price Momentum 0/100
No bullish technical signals detected. The stock lacks upward price momentum currently.
-
News Sentiment 5/100
No sentiment data available
What does this score mean?
The MoonshotScore rates MTEM's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Frequently Asked Questions
What does Molecular Templates, Inc. do?
Molecular Templates, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing biologic therapeutics for cancer and other serious diseases. The company's core technology is its proprietary biologic engineered toxin body (ETB) drug platform. This platform is used to create targeted therapies that deliver a potent toxin to cancer cells, selectively killing them while sparing healthy cells. The company is currently advancing a pipeline of ETB-based therapies through clinical trials, with the goal of developing new and effective treatments for cancer patients.
Is MTEM stock a good buy?
MTEM stock represents a high-risk, high-reward investment opportunity. The company's innovative ETB platform and promising clinical pipeline offer significant potential for growth. However, as a clinical-stage company with no currently approved products, Molecular Templates faces substantial risks, including clinical trial failures and regulatory hurdles. The company's negative profit margin reflects its investment in research and development. Investors should carefully consider their risk tolerance and conduct thorough due diligence before investing in MTEM. Positive clinical trial results and strategic partnerships could drive significant upside, while setbacks could negatively impact the stock price.
What are the main risks for MTEM?
The main risks for Molecular Templates include clinical trial risk, regulatory risk, competition risk, and financial risk. Clinical trial failures could delay or halt the development of ETB candidates, undermining the company's pipeline. Regulatory hurdles could delay or prevent the approval of ETB candidates, limiting the company's ability to commercialize its products. Competition from other biotechnology companies could limit market share and pricing power. The company's limited financial resources could constrain its ability to fund research and development and commercialization efforts.
Is MTEM a good stock to buy?
Whether MTEM is a suitable investment depends on your goals, risk tolerance, and time horizon. Evaluate Molecular Templates, Inc.'s revenue growth, profit margins, debt levels, and valuation relative to peers. This is not financial advice.
What is the MTEM MoonshotScore?
The MoonshotScore rates MTEM from 0 to 100 across growth potential, financial health, market momentum, and risk factors. Scores above 70 suggest strong potential, 50-70 moderate, and below 50 warrants caution. It is recalculated daily using the latest market data. This score is informational only.
How often is MTEM data updated?
MTEM prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What do analysts say about MTEM?
Analyst coverage for MTEM includes consensus ratings (buy, hold, sell), 12-month price targets, and earnings estimates from major research firms. Key data points: consensus target price, number of covering analysts, recent upgrades or downgrades, and earnings beat/miss history. See the Analyst Consensus section on this page.
What are the risks of investing in MTEM?
Risk categories for MTEM include market risk, company-specific risk (management, competition), financial risk (debt, cash burn), and macroeconomic risk (rates, inflation). Beta above 1.0 indicates higher volatility than the S&P 500. Review the Risk Factors section on this page for details. All investments carry risk of loss.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Data provided for informational purposes only.
- Stock data pending update. Financial data is based on the most recent available information.